The Evolution of Coronary Stenting: From Permanent Cages to Temporary Scaffolds

The treatment of coronary artery disease (CAD) has undergone a dramatic evolution over the past four decades. Percutaneous transluminal coronary angioplasty (PTCA) gave way to bare-metal stents (BMS) to combat acute vessel closure and restenosis, which were then largely supplanted by drug-eluting stents (DES) to reduce neointimal hyperplasia. However, each of these technologies leaves a permanent metallic implant within the coronary artery. This persistent foreign body is associated with long-term adverse events, including very late stent thrombosis, chronic inflammation, neoatherosclerosis within the stent, and impaired coronary vasomotion. The concept of a transient support structure that vanishes once the vessel has healed—a bioresorbable scaffold—emerged as a potential "holy grail" to overcome these enduring limitations. By providing temporary mechanical support and localized drug delivery, then completely dissolving, bioabsorbable stents (often referred to as Bioresorbable Vascular Scaffolds or BRS) aim to restore the artery to a more natural, functional state, free from a permanent implant.

Material Platforms and Degradation Kinetics

The fundamental challenge in BRS design lies in balancing sufficient mechanical integrity during the critical period of vascular healing (typically 6 to 12 months) against a desirable degradation rate that avoids late inflammatory responses. To date, two primary material platforms have dominated the landscape: semi-crystalline polymers and bioabsorbable metallic alloys.

Poly-L-Lactic Acid (PLLA) Based Scaffolds

PLLA is a thermoplastic polymer with a well-established safety profile in medical applications such as absorbable sutures and bone screws. The first commercially available device, the Absorb BVS (Abbott Vascular), was constructed from a backbone of high-molecular-weight PLLA coated with a poly(D,L-lactide) (PDLLA) polymer eluting everolimus. PLLA degrades primarily through bulk hydrolysis of its ester linkages. Over approximately 12 months, the polymer chains cleave into smaller oligomers, leading to a loss of radial strength. The final degradation products are lactic acid monomers, which are metabolized in the Krebs cycle to carbon dioxide and water. While effective in providing support, the first-generation PLLA scaffolds required a strut thickness of approximately 150 micrometers to achieve adequate radial strength. This thickness, significantly greater than contemporary cobalt-chromium DES (typically under 80 micrometers), created unfavorable local hemodynamics, contributing to increased thrombogenicity and procedural complexity. Subsequent iterations, such as the DESolve scaffold (Elixir Medical), utilized a modified polylactide-based polymer with a controlled degradation rate to mitigate acute recoil and late luminal loss.

Fully Bioabsorbable Metallic Scaffolds

Metals offer inherent advantages over polymers, including superior tensile strength, ductility, and radiopacity, potentially allowing for thinner strut designs. Magnesium, an essential ion in the human body, serves as the primary candidate. The Magmaris scaffold (Biotronik) is a sirolimus-eluting scaffold composed of a proprietary magnesium alloy. Degradation occurs through surface corrosion, forming a magnesium hydroxide layer that gradually converts to amorphous calcium phosphate, which is then remodeled into the local tissue. The resorption process is significantly faster than PLLA, typically completing within 12 months. Initial clinical data from the BIOSOLVE-II and BIOSOLVE-III trials demonstrated low target lesion failure (TLF) rates and a favorable safety profile, with strut thickness remaining around 150 microns but expected to trend downward with improved metallurgy. The magnesium ion byproducts are also thought to have potential anti-proliferative and pro-endothelializing properties, which represent an area of active investigation.

Degradation Dynamics and Clinical Implications

The temporal profile of scaffold degradation is critical. To prevent restenosis and avoid late events, the scaffold must maintain mechanical integrity (radial strength and recoil resistance) for at least 6 months until the vessel wall has healed and vascular remodeling is complete. For PLLA, this support phase lasts 6-9 months, with structural integrity fully lost by 12-18 months. Premature degradation can lead to late recoil and malapposition, while incomplete degradation can leave polymer flakes that may trigger thromboinflammatory responses. Balancing drug elution kinetics with the degradation timeline is a complex interplay; the anti-proliferative drug must be released during the proliferative phase of healing to suppress neointimal growth, yet the degraded polymer must be sufficiently biocompatible to allow for functional endothelialization.

Critical Analysis of Clinical Trial Data and Lessons Learned

The initial enthusiasm for BRS was tempered by clinical outcomes that fell short of expectations compared to state-of-the-art DES. A deep dive into the evidence provides a roadmap for the refinement of this technology.

The Absorb BVS: The Pivotal Trial Landscape

The ABSORB clinical trial program was the most comprehensive investigation of a BRS device. ABSORB Cohort B demonstrated the feasibility of the technology, with evidence of vasomotion restoration at 2 years. The pivotal ABSORB III trial, which randomized 2,008 patients to either Absorb BVS or Xience DES, met its primary 1-year endpoint of non-inferiority for target lesion failure (TLF). However, significant alarm was raised by subsequent longer-term data. The ABSORB II trial showed no improvement in vasomotion at 3 years and a higher rate of target lesion failure. Pooled patient-level analyses from ABSORB III and ABSORB II revealed a significantly higher rate of scaffold thrombosis (ST) with the Absorb BVS, particularly very late ST (occurring beyond 1 year), compared to the metallic Xience DES. This finding effectively halted the widespread clinical adoption of the Absorb BVS and led to its eventual withdrawal from the commercial market.

The Emergence of the PSP Protocol

Post-hoc analyses of the ABSORB trials identified that operator adherence to a specific implantation protocol—termed PSP (Pre-dilatation, Sizing, Post-dilatation)—was a powerful independent predictor of outcomes. Pre-dilatation ensures the lesion is adequately prepared. Precise Sizing using intravascular imaging (IVUS or OCT) is critical to avoid implanting a bulky PLLA scaffold into a small vessel, which is a strong predictor of ST. Post-dilatation with a high-pressure, non-compliant balloon (0.5mm larger than the scaffold) is essential to ensure adequate strut apposition and expansion. When PSP was performed rigorously, the outcomes of the Absorb BVS approached those of the Xience DES. This underscored that BRS, unlike highly flexible metallic DES, demands a meticulous, standardized approach to implantation, with zero tolerance for geometric errors like underexpansion or malapposition. Long-term follow-up studies confirmed that lesions treated with optimal PSP had significantly lower TLF and ST rates.

Contemporary Scaffolds: Building on Lessons Learned

Newer BRS devices have incorporated these insights into their design and clinical development. The DESolve scaffold demonstrated the ability to self-correct acute malapposition after slow balloon deflation. The Magmaris magnesium scaffold showed promising 12-month data with low TLF (4.3%) and a notably low early scaffold thrombosis rate, attributed to its faster endothelialization and more favorable degradation profile. The BIOSOLVE-IV registry continues to evaluate the long-term performance of magnesium-based BRS. The Fantom scaffold (REVA Medical) utilized a tyrosine-derived polycarbonate polymer, providing high radial strength and radiopacity with a thinner strut design (125 microns). These devices represent a deliberate move away from the limitations of the first-generation PLLA scaffolds.

Strategic Advantages: The "Leave Nothing Behind" Paradigm

Despite the clinical setbacks, the conceptual advantages of BRS remain compelling for specific patient groups and clinical scenarios. The long-term goal is not merely to treat a stenosis, but to restore normal vascular physiology and preserve future revascularization options.

Restoration of Vasomotion and Endothelial Function

After complete resorption, the treated arterial segment is no longer constrained by a rigid metallic cage. Late lumen enlargement and a return of cyclic pulsatility have been documented in imaging studies. Perhaps more importantly, the endothelium can recover its vasoactive function, including endothelium-dependent vasodilation in response to stress and acetylcholine. This is in stark contrast to permanent DES, which leave a segment of artery with permanently impaired vasomotion, increasing the risk of future ischemic events at the edges of the stent. This restoration of physiological function is a unique attribute of BRS that no permanent implant can offer.

Facilitating Future Revascularization

The absence of permanent metallic layers makes future percutaneous coronary intervention (PCI) technically simpler. If a patient with a BRS develops a new stenosis within the scaffold or at the edges, a standard DES can be implanted without the difficulty of crossing multiple layers of metal or the risk of metal fatigue and fracture from drilling. Furthermore, subsequent coronary artery bypass grafting (CABG), if ever needed, is technically easier and potentially safer, as the suture lines are in a pliable, native vessel rather than a rigid, calcified metallic tube.

Compatibility with Advanced Imaging

Permanent metallic stents create significant blooming artifacts on computed tomography angiography (CTA), degrading image quality and obscuring the lumen for non-invasive follow-up. A fully resorbed scaffold leaves behind no such artifact, allowing for high-quality, unobstructed CTA assessment of the coronary arteries. As CTA becomes the first-line test for stable chest pain evaluation, this compatibility grows in clinical importance.

Persistent Challenges and Patient Selection

Current BRS technology is not a one-size-fits-all solution. Understanding its limitations is critical for safe and effective application.

Mechanical Integrity vs. Deliverability

The fundamental trade-off remains the inverse relationship between mechanical strength and device profile. Polymers and bioabsorbable metals lack the mechanical properties of cobalt-chromium or platinum-chromium alloys. Achieving sufficient radial strength to resist chronic recoil requires thicker struts, which in turn increase the crossing profile and reduce deliverability. This makes BRS significantly more challenging to implant in tortuous, calcified, or diffusely diseased vessels. The risk of strut fracture during deployment in challenging anatomy is a real concern.

Optimal Lesion and Patient Selection

Extensive clinical data guide appropriate patient selection. Ideal candidates for BRS are those with stable, non-complex lesions in larger epicardial vessels (typically between 2.75 mm and 4.0 mm in diameter). Focal, non-calcified plaques (Type A or low complexity B1 lesions) are the most suitable targets. Patients presenting with acute coronary syndromes (ACS), such as STEMI or NSTEMI, have been studied, but the presence of thrombus and plaque rupture adds a layer of complexity that may increase risk. BRS are generally contraindicated in heavily calcified lesions, severely tortuous vessels, bifurcation lesions with a large side branch, and in patients with a known allergy to the polymer or drug.

Dual Antiplatelet Therapy (DAPT) Considerations

The goal of BRS is to eventually allow for minimal DAPT. However, the higher early thrombotic risk associated with the bulky struts paradoxically mandates a longer DAPT duration in the early years of adoption. Current consensus guidelines recommend DAPT for at least 12 months after BRS implantation, often extending to 24 months or more, especially for PLLA scaffolds, until complete resorption has occurred. This partially negates the advantage of BRS for patients who are high-risk for bleeding or who require early non-cardiac surgery.

The Future of Bioresorbable Technology: Refinement and Precision

The lessons from the Absorb BVS era have not halted the field; rather, they have realigned it. The next generation of BRS is focused on precision engineering, enhanced materials, and strict procedural execution.

Ultrathin Struts and Advanced Polymer Chemistry

Future scaffolds aim for a massive reduction in strut thickness, targeting 100-120 microns or less. This is being achieved through polymer orientation techniques, composite materials, and new polymer chemistries (such as tyrosine-based polycarbonates and salicylate-based polymers) that offer superior strength-to-weight ratios. A thinner strut directly translates to reduced flow disturbance, lower thrombogenicity, and improved deliverability. Devices in development are also engineering controlled, linear degradation rates that avoid the sudden loss of strength seen in earlier platforms.

Precision Implantation and Imaging Guidance

Mandatory intravascular imaging (OCT/IVUS) is likely to become standard of care for BRS implantation. OCT provides unparalleled visualization of strut apposition, edge dissection, and tissue coverage. Future integrated catheter systems or devices with improved radiopaque markers will facilitate precise sizing and post-dilatation. The "PSP" protocol will be refined into a mandatory checklist, similar to safety checks in aviation, ensuring that every BRS is deployed under optimal conditions. Dedicated operator training and certification may be required.

Paving the Way for Targeted Drug and Gene Delivery

The degradable polymer matrix offers a unique platform for controlled release of multiple therapeutic agents beyond standard anti-proliferatives. Researchers are investigating the release of CD34 antibodies to trap circulating endothelial progenitor cells and accelerate endothelialization. Anti-inflammatory agents could modulate the healing response. In the future, bioabsorbable scaffolds could serve as a platform for local gene therapy, delivering vectors that promote angiogenesis or stabilize plaque. This represents a fundamental shift from a simple mechanical implant to a sophisticated, programmable therapeutic delivery system.

Conclusion

Bioabsorbable stents for coronary artery disease remain one of the most innovative concepts in interventional cardiology, despite the significant clinical hurdles encountered. The journey has evolved from unbridled optimism about a revolutionary technology to a more nuanced, evidence-based understanding of its specific strengths and limitations. The fundamental advantages—restoring vasomotion, facilitating future revascularization, avoiding the long-term sequelae of a permanent metallic implant—are too compelling to abandon. With advanced materials that enable thinner, stronger struts, mandatory procedural optimization protocols (PSP with imaging guidance), and careful patient selection, second- and third-generation BRS are poised to carve out a durable, viable niche in the armamentarium for treating CAD, offering a true alternative to the permanent metal cage, particularly for younger patients with discrete, non-complex lesions in large vessels.